Physician profile
Michael Raymond Handleton
NPI 1235111410
$3,458.67
in general payments reported to CMS, 2019-2025
29 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $38.71 · 2021: $235 · 2022: $797 · 2023: $835 · 2024: $629 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $513.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $434.68 | 2019-2025 | |
| Abbvie INC. | $398.97 | 2023-2025 | |
| Amgen INC. | $206.52 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $140.80 | 2022-2024 | Gardasil 9, Gardasil, Steglatro |
| Glaxosmithkline, LLC. | $109.36 | 2019-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $95.06 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $87.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.53 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $76.56 | 2019-2022 | |
| Abbott Laboratories | $69.77 | 2023-2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $68.24 | 2025 | Sapien 3 Ultra Resilia |
| Dexcom, INC. | $64.21 | 2022-2024 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $40.88 | 2025 | |
| Sanofi Pasteur INC. | $29.75 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $23.28 | 2025 | |
| Biogen, INC. | $19.20 | 2021 | |
| Astellas Pharma US INC | $18.02 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $17.21 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $15.28 | 2022 | |
| Corcept Therapeutics | $14.52 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $14.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.08 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $12.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.47 | 2022 | |
| Amarin Pharma, INC. | $12.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Handleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.